Climb Bio (CLYM)
Develops antibody programs for immune-mediated diseases.
$16.20
Pre-market+1.16 (+7.71%)
At close$15.04(+1.48%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Insiders3 holders · as of Jun 30, 2026 | 0.46% | 261.3K shares | |
| Strategic holders1 holder · as of Jan 7, 2026 | 5.94% | 3.40M shares | |
| Otherremainder | 93.60% | 53.60M shares |
57.26M company shares as of Aug 22, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 29, 2026 | Aoife Brennandirector, officer: President and CEO | Sale | 30,902 | $13.17 | 87,731 |
| Feb 26, 2026 | Stephen Basil Thomasdirector | Sale | 16,313 | $7.01 | 154,657 |
| Feb 25, 2026 | Stephen Basil Thomasdirector | Sale | 33,687 | $7.00 | 170,970 |
| Feb 13, 2026 | Stephen Basil Thomasdirector | Sale | 10,000 | $5.81 | 204,657 |
| Feb 12, 2026 | Stephen Basil Thomasdirector | Sale | 90,000 | $5.23 | 214,657 |
| Jan 5, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 7,111 | $3.50 | 3,403,429 |
| Dec 11, 2025 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 213,099 | $2.18 | 3,294,856 |
| Dec 12, 2025 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 101,462 | $2.86 | 3,396,318 |
CongressHouse and Senate disclosures
Not reported.